New drug delivery systems in Taiwan are registered by submitting a New Drug Application (NDA) to the TFDA, including detailed data on the delivery mechanism’s safety, efficacy, and stability. Applicants must demonstrate Good Manufacturing Practice (GMP) compliance and provide supporting clinical studies. Specialized delivery systems may require bridging studies to confirm their applicability in Taiwan.
